Tanespimycin nanoemulsion - Biogen Idec

Drug Profile

Tanespimycin nanoemulsion - Biogen Idec

Alternative Names: CNF 101; CNF 1010

Latest Information Update: 09 Oct 2007

Price : $50

At a glance

  • Originator Biogen Idec
  • Class Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules
  • Mechanism of Action Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 17 May 2007 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
  • 17 May 2007 Discontinued - Phase-I for Chronic myeloid leukaemia in USA (IV-infusion)
  • 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top